Senior Analytics Engineer

Evvy launches at-home UTI Test to expedite care. The pervasive issue of urinary tract infections, which stand as the most common infection among women in the United States, has long been compounded by a diagnostic process that frequently leads to frustration and delayed relief. For countless individuals, the experience is a cyclical nightmare of symptoms, clinic visits, and treatments that may not even be effective, as research indicates nearly half of women are prescribed an antibiotic that is ill-suited to their specific infection. This diagnostic gap not only prolongs discomfort but also contributes to the rise of antibiotic resistance and the prevalence of recurring infections, which affect approximately one in four women. In response to this widespread challenge, women's health startup Evvy has introduced a new at-home testing solution designed to overhaul this outdated standard of care by providing rapid, precise, and actionable insights directly to consumers, aiming to break the cycle of ineffective treatment and recurrent symptoms through advanced technology. 1. A new approach to uti diagnostics. Evvy's new UTI+ Test represents a significant step forward in urinary health diagnostics by leveraging the power of polymerase chain reaction (PCR) technology from a simple, at-home urine sample. This advanced molecular testing method is engineered to detect the specific genetic material of 12 common uropathogens, offering a far more comprehensive analysis than traditional culture methods, which can often miss key microbes. Furthermore, the test simultaneously screens for seven antibiotic-resistance genes, providing crucial information that guides effective treatment from the outset. The user experience is designed for maximum convenience and speed, eliminating the need for in-person clinic visits and lengthy waits. After collecting a urine sample at home, the user sends it to Evvy's lab for analysis. The company guarantees results within one business day of the lab receiving the sample, a dramatic reduction in turnaround time compared to standard cultures. This expedited process is coupled with a telehealth component, allowing an Evvy clinician to review the results and, if necessary, provide a same-day prescription that can be picked up at a local pharmacy. This innovative model directly addresses the core failures of the current standard of care for UTIs, which has been described by Evvy's co-founder and CEO, Priyanka Jain, as "fundamentally broken." Traditional urine cultures, long the gold standard, present multiple challenges for patients. They can take several days to yield results, a critical delay for someone experiencing acute pain and discomfort. More troublingly, these cultures frequently fail to identify the majority of pathogens responsible for an infection, leading to a high rate of incorrect antibiotic prescriptions. This guesswork not only fails to resolve the immediate infection but can also contribute to the development of antibiotic-resistant strains and disrupt the body's natural microbiome, often leading to a recurring cycle of symptoms. By providing a detailed report on both the specific pathogen causing the infection and its potential resistance to certain antibiotics, the UTI+ Test empowers clinicians to make evidence-based decisions, increasing the likelihood of prescribing a medication that will work the first time and offering patients a much-needed path to faster, more reliable relief. 2. Integrating Vaginal Health and broader context. The launch of the UTI+ Test is seamlessly integrated with Evvy's flagship product, the Vaginal Health Test, reflecting a more holistic understanding of female pelvic health. Emerging research has highlighted a critical connection between the vaginal and urinary microbiomes, showing that bacteria originating in the vaginal microbiome can often "seed" the urinary tract, leading to infections. This connection underscores the importance of a comprehensive diagnostic approach. Evvy's own data supports this, revealing that 47% of its users who reported recent UTIs also had UTI-related bacteria present in their vaginal microbiome. For individuals, especially those suffering from recurrent UTIs, this integrated perspective is invaluable. By using both the UTI+ Test and the Vaginal Health Test, users and their clinicians can gain a clearer picture of the root causes of their symptoms, determining whether an imbalance in the vaginal microbiome might be a contributing factor to their ongoing urinary issues. This dual insight enables more targeted and preventative care strategies that go beyond simply treating the acute infection. The introduction of this new diagnostic tool is the latest in a series of strategic expansions for Evvy, solidifying its position as a key innovator in the women's health technology sector. This move follows the company's addition of fertility insights to its vaginal microbiome test earlier in the year and the publication of a peer-reviewed study that found Evvy's platform improved the diagnosis and treatment of bacterial vaginosis, with over 75% of patients reporting symptom relief. This scientific validation helps build trust in its direct-to-consumer model. The UTI+ Test is available in most U.S. states for a one-time purchase price of $248, with a discount for subscribers. While Evvy is a prominent player, it operates in a growing market that includes other at-home testing companies like Juno Bio, which also offers vaginal microbiome analysis and health coaching. This competitive landscape signals a broader industry shift toward empowering women with more accessible, science-backed health solutions that move beyond traditional, and often inadequate, clinical pathways. 3. A shift in women's healthcare. The development and launch of this at-home diagnostic tool marked a significant pivot in how urinary tract health was approached, moving care from a reactive, often inefficient clinical model to a proactive, patient-centered one. For decades, the narrative surrounding UTIs was one of resignation, with many women being told that their recurring infections were simply a matter of "bad luck." This new technology directly challenged that notion by providing concrete scientific data that illuminated the specific microbial causes of infection. The ability to identify not only the pathogen but also its antibiotic-resistance markers from home fundamentally altered the patient journey. It replaced waiting and uncertainty with speed and precision, equipping both patients and providers with the necessary information to select the most effective treatment promptly. This shift was more than a matter of convenience; it represented a move toward personalized medicine that had the potential to curb the overuse of broad-spectrum antibiotics and mitigate the growing crisis of antibiotic resistance. Ultimately, this innovation empowered individuals with a deeper understanding of their own bodies and gave them a more active role in managing their health, transforming a frustrating cycle of illness into an opportunity for informed and effective intervention.

Evvy launches New at-home UTI Test. Evvy has launched the Evvy UTI+ Test, an at-home urine test that uses PCR technology to detect 12 key uropathogens and 7 antibiotic resistance markers. Results are delivered in one business day. Eligible patients can receive same-day, targeted prescription care based on their results. Standard urine cultures can miss up to 60-70% of pathogens, and results often take days to return. Nearly one in two women receive an antibiotic that may not effectively address their infection, leading to prolonged symptoms, repeat appointments, and unnecessary antibiotic exposure. "At Evvy, we believe women deserve better than guesswork," said Dr. Kate McLean, OBGYN and Chief Medical Officer at Evvy. "We designed the UTI+ Test to solve a big failure of current UTI care: incomplete detection. By using PCR to identify 12 key pathogens, we can treat UTIs with accuracy and precision. The result is simple but profound - patients finally get better without the trial-and-error approach that has plagued UTI care for generations." UTIs are the most common infection in US women. One in four women experience recurring UTIs. Evvy is known for its vaginal microbiome test kits. Research shows that the vaginal microbiome can play a role in urinary health by acting as a reservoir for UTI-causing bacteria. In Evvy's dataset, 47% of users who reported a recent UTI had UTI-related bacteria detected in their vaginal microbiome. The UTI+ Test is available in the US except Alaska, Hawaii, and New York at $248, or $218 with a subscription.

Evvy rethinks vaginal microbiome and UTI diagnostic care. ByGeri Stengel, Contributor. Geri Stengel writes about the success factors of women entrepreneurs. Women who struggle with urinary tract infections that keep coming back, stubborn bacterial vaginosis, or persistent vaginal discomfort know the cycle all too well: a short appointment, a limited test, another round of antibiotics, and reassurance that "everything looks normal." For millions of women, the issue isn't their bodies - it's a diagnostic system stuck in decades-old tools. Evvy, cofounded by Priyanka Jain, is focused on vaginal healthcare and is working to change that system by uncovering what standard testing often misses, using an extensive dataset of vaginal microbiome samples. Today, Evvy launched its UTI+ Test, an at-home urine test that uses PCR technology to detect 12 uropathogens and seven antibiotic-resistance markers, delivering results within one business day. It aims to give women faster, clearer insight into infections that represent a $10.4 billion global market today and are projected to reach $15 billion by 2032. The scale of BV and UTI problems. Bacterial vaginosis and urinary tract infections are among the most common reasons women seek medical care. Yet the diagnostic tools remain outdated. The prescription drug market for bacterial vaginosis is forecast to more than double over the next decade, increasing from $1.1 billion in 2023 to an estimated $2.5 billion by 2033. UTIs drive millions of clinical visits each year and absorb billions in treatment costs - yet nearly half of women receive antibiotics that are not considered first-line therapy. Part of the challenge is that standard urine cultures miss up to 50% to 70% of pathogens in women with symptoms. Vaginal testing, meanwhile, still often relies on a clinician's visual reading under a microscope or a "whiff test" - using your nose to notice an odor. "The whole system does not want women to have more agency, more information, and it's wild how much inertia there is to fight against," explained Jain, Evvy's CEO. "It shows why women have gone so long without real answers." ForbesWomen: Get the ForbesWomen newsletter, and supercharge your mission with success stories, tips and more. Evvy has raised $19 million in funding, backed by General Catalyst and Left Lane Capital. "Evvy's groundbreaking platform is changing the way we understand and care for the female body," said Laura Sillman, VP at Left Lane Capital. How Evvy's model improves vaginal and UTI care. Evvy's founding thesis is straightforward: Women have been underserved because medicine has lacked high-resolution tools to understand the vaginal and urinary microbiomes. Evvy can detect more than 700 bacteria and fungi from a single swab, offering a level of detail that older methods cannot approach. A peer-reviewed validation found that Evvy reached 93.1% sensitivity and 90% specificity. Evvy's at-home vaginal test has become core to its clinical research, including a published outcomes study that found 75.5% of users experienced symptom relief after personalized treatment guided by microbiome results, with far lower return-of-symptom rates than with standard care. Today, Evvy has expanded beyond vaginal testing with the launch of UTI+, a PCR-based urine test that identifies 12 pathogens and seven antibiotic-resistance markers. The test offers a one-business-day turnaround and enables targeted treatment within 24 hours - an essential shift from slow cultures and empiric antibiotic prescribing. The barriers in Women's Health care. Clinical inertia in Women's Health testing. Evvy's work also exposes deeper structural challenges. Traditional diagnostics were not designed to distinguish between mixed infections, antibiotic-resistance markers, or subtle microbiome shifts that can trigger ongoing symptoms. Clinicians often lack tools that go beyond broad categories like "BV-positive" or "UTI-negative." Changing that ecosystem requires research, which Evvy has aggressively pursued. The company has ongoing clinical trials in BV, UTIs, fertility, IVF outcomes, and menopause-related vaginal changes. Its scientific advisory relationships span leading academic and clinical institutions. More than 2,000 healthcare providers have interacted with or referred patients to Evvy. Still, early skepticism was real. Some clinicians were concerned that giving women detailed microbial data would overwhelm them. Evvy found the opposite: Clarity reduces anxiety. Most patients want more information about their bodies, not less. Educating payors and policymakers: access and reimbursement. Today, Evvy remains a cash-pay service, not because of strategy but because insurers are reluctant to reimburse more advanced diagnostics. Legacy methods like microscopy or the whiff test cost very little, and payors have not yet adapted to microbiome science. Evvy is working to change that through clinical trials that link microbiome profiles to high-cost issues such as unsuccessful IVF cycles, preterm birth risk, and persistent vaginal symptoms that often lead to repeated visits and antibiotic courses. Demonstrating cost savings and clinical impact will be essential to shifting coverage. Navigating algorithm bias in Women's Health. Digital platforms present another challenge uniquely familiar to women's health companies. Content containing medically accurate phrases like "vaginal health," "BV symptoms," or "UTI testing" can be flagged or down-ranked by social media and search algorithms, limiting reach. This environment makes community-building and education difficult. Yet it also reinforces why direct-to-consumer access matters: Women are seeking answers outside traditional medical systems, and they want tools that offer clarity rather than more ambiguity. Evvy's patient-first care approach. What distinguishes Evvy is not only advanced testing, but how results translate into care. Evvy pairs test findings with personalized treatment plans by doctors designed to address the root cause of symptoms and prevent recurrence. The company provides follow-up guidance and care pathways tailored to an individual's microbial profile. "We fix the symptom, we fix the problem, and we make sure it doesn't come back," Jain said. "And we do all of that while giving women a good experience where they feel understood and listened to." The company's patient-centered approach is reflected in a striking metric: 98% of users consent to participate in research, which strengthens the data available to improve women's health outcomes. "Through this strategic partnership with Evvy, we aim to create a patient-first experience that helps women more conveniently access the treatments they need for their health," noted Elizabeth Stephens, director, Women's Health Strategy, Advocacy, and Partnerships at Organon. A new standard for vaginal and UTI care and beyond. Evvy's expanding role in fertility and menopause. Beyond UTIs and BV, Evvy is exploring how the vaginal microbiome affects fertility and pregnancy. Early research shows connections between microbiome imbalances and inflammation that can affect implantation. Evvy is working with fertility clinics to explore how microbiome-guided care might improve IVF outcomes. The company is also developing approaches for menopause, when estrogen decline reshapes the vaginal microbiome and increases susceptibility to infection and irritation. Evvy is studying how personalized hormonal and microbiome treatments may better support midlife health. How precision tools improve women's UTI and BV care. Evvy's work is part of a broader shift in women's health toward tools that offer specificity rather than broad categories, answers rather than assumptions, and prevention rather than repeated cycles of treatment. The December launch of UTI+ signals how far the company has come and how much opportunity lies ahead. As the medical field continues to recognize the importance of the vaginal and urinary microbiomes, Evvy's data-driven model offers a path toward care that is faster, more accurate, and more aligned with women's lived experiences. For many, it may finally provide the clarity they have long been denied, setting a new bar for vaginal microbiome and UTI diagnostic care.